<DOC>
	<DOCNO>NCT02838433</DOCNO>
	<brief_summary>The impressive clinical response obtain immune checkpoint inhibitor ( anti-PD-1/PDL-1 , anti-CTLA-4 ) indicate presence preexist antitumor immune response might require efficacy highlight critical role antitumor T cell immunity . Recent progress field tumor immunology underline critical role CD4 helper 1 T lymphocyte ( TH1 ) control innate adaptive anticancer immunity . Therefore , monitor tumor specific TH1 response could relevant cancer patient . In order monitor tumor-specific CD4 Th1 responses cancer patient , investigator team previously describe novel promiscuous peptide ( refer UCP : Universal Cancer Peptides ) derive human telomerase ( TERT ) , prototype share tumor antigen . By use UCP-based immuno-assay , UCP specific Th1 immune response evaluate study melanoma treatment .</brief_summary>
	<brief_title>Study Anti-telomerase T CD4 Immunity Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>patient melanoma , stade , without history anticancer treatment ( surgery , chemotherapy , target therapy , immunotherapy ... ) except patient stade IV melanoma immunotherapy target therapy consider . In case , firstline chemotherapy treatment allow write informed consent patient immunosuppressive treatment active autoimmune disease , HIV , hepatitis C B virus patient guardianship , curatorship protection justice , pregnant woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>